Aspirin/clopidogrel - Sanofi

Drug Profile

Aspirin/clopidogrel - Sanofi

Alternative Names: Clopidogrel/aspirin - Sanofi; ComPlavin; DuoCover; DuoPlavin

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antiplatelets; Antipyretics; Pyridines; Salicylic acids; Small molecules; Thienopyridines
  • Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute coronary syndromes

Most Recent Events

  • 31 Mar 2015 Launched for Acute coronary syndromes in Greece, Italy, France, Portugal, Poland, Czech Republic, Croatia, Slovenia, Lithuania, Switzerland, Georgia, Russia and Ukraine (PO) before March 2015
  • 31 May 2011 Sanofi-aventis is now called Sanofi
  • 15 Mar 2010 Registered for Acute coronary syndromes in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top